-------------------------------------------------------------------------
-------------------------------------------------------------------------
Stock options exercised or
cancelled 28,453 208,558 -
Stock-based compensation expense - - -
Net loss and comprehensive loss
for the three-month period ended
September 30, 2008 - - -
-------------------------------------------------------------------------
Balance, September 30, 2008 23,215,160 160,471,098 4,492,251
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Total
Stock Shareholders'
Options Deficit Equity
-------------------------------------------------------------------------
$ $ $
Balance, July 1, 2007 1,538,396 (89,691,569) 50,322,897
-------------------------------------------------------------------------
Adjustment to opening deficit
for change in accounting policy
related to financial instruments - 1,650,000 1,650,000
Issued pursuant to private
placement, net - - 23,968,567
Issued as additional consideration
regarding Ellipsis
Neurotherapeutics Inc. - - 1,890,976
Stock options exercised or
cancelled (166,534) - 252,644
Stock-based compensation expense 1,721,873
'/>"/>
| SOURCE Transition Therapeutics Inc. Copyright©2008 PR Newswire. All rights reserved |